Novartis expects profit and sales to grow further this year after beating analysts’ expectations, boosted by revenue from its ...
Novartis on Friday posted quarterly adjusted net income well above analyst estimates on higher drug revenues. Fourth-quarter ...
Swiss drug major Novartis AG (NVS) reported Friday that its fourth-quarter net income plunged to $2.82 billion from last year's $8.48 ...
Jefferies analyst Peter Welford maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...
To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s ...
AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...
SALES FORECAST: Novartis's sales are forecast at $12.78 billion, according to analysts' estimates compiled by Visible Alpha. This compares with $11.42 billion the year before. Shares rose 5.1% over ...
In addition to the partnership with Steinfeld and Sykes, Novartis is collaborating on awareness efforts and advocacy events ...
ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...
The roller-coaster ride for Novartis—as it uses every bit of its legal muscle to extend Entresto's market exclusivity—took ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback